Market Segmentation:
- By Formulation Type
- Injections
- Ready-to-Use Mixtures
- Oral Solutions
- Others
- By End-User
- Hospitals
- Neonatal Intensive Care Units
- Pediatric Intensive Care Units
- Specialty Clinics
- Homecare
- Others
- By Packaging Type
- Ampoules
- Vials
- Pre-filled Syringes
- Others (bags, bottles)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
The current (2023 est.) market size is USD 130 million.
Increasing preterm births, rising respiratory disorders in neonates, growing NICU infrastructure and ventilation capabilities, advances in ready-to-use formulations.
Stringent regulatory policies, limited eligible patient pool, high costs, safety concerns in off-label use cases.
Injections segment leads with over 75% share owing to precision in dosage and stability.
Avadel, Baxter International, Fresenius Kabi, Claris Lifesciences, Pfizer.
North America will account for over 55% share, growing at 5% CAGR reaching USD 127 million in 2031.
Rising preterm births, increasing apnea cases, growing NICU infrastructure, new product launches.